Skip to main content
AAN.com

Abstract

Objective:

Comorbidities are common in multiple sclerosis (MS) and adversely affect health outcomes. However, the effect of comorbidity on treatment decisions in MS remains unknown. We aimed to examine the effects of comorbidity on initiation of injectable disease-modifying therapies (DMTs) and on the choice of the initial DMT in MS.

Methods:

We conducted a retrospective observational analysis using population-based health administrative and linked clinical databases in 3 Canadian provinces. MS cases were defined as any individual with ≥3 diagnostic codes for MS. Cohort entry (index date) was the first recorded demyelinating disease-related claim. The outcomes included choice of initial first-line DMTs and time to initiating a DMT. Logistic and Cox regression models were used to examine the association between comorbidity status and study outcomes, adjusting for sex, age, year of index date, and socioeconomic status. Meta-analysis was used to estimate overall effects across the 3 provinces.

Results:

We identified 10,698 persons with incident MS, half of whom had ≥1 comorbidities. As the total number of comorbidities increased, the likelihood of initiating a DMT decreased. Comorbid anxiety and ischemic heart disease were associated with reduced initiation of a DMT. However, patients with depression were 13% more likely to initiate a DMT compared to those without depression at the index date (adjusted hazard ratio 1.13; 95% confidence interval 1.00–1.27).

Conclusions:

Comorbidities are associated with treatment decisions regarding DMTs in MS. A better understanding of the effects of comorbidity on effectiveness and safety of DMTs is needed.
Multiple sclerosis (MS) is a chronic disease of the CNS.1 The emergence of disease-modifying therapies (DMTs) in the 1990s advanced MS management, as randomized clinical trials demonstrated reductions in relapse rates and disability progression over short periods.2 Comorbidities are common in individuals with chronic diseases, including MS,3 and adversely affect health outcomes.48 For example, there are concerns regarding increased hepatotoxicity due to drug–drug interactions between interferon-β and lipid-lowering agents.9 Fingolimod is associated with sudden cardiac-related death, and is contraindicated in persons with preexisting cardiac disease or stroke.10 In other chronic diseases such as hypertension and cancer, comorbidities may affect treatment decisions and further affect disease outcomes,5 by changing the choice of whether to start treatment and the specific choice of treatment.11,12 However, no studies have examined comorbidity and treatment decisions in patients with MS. We examined the effects of comorbidity on the use of DMTs in MS with respect to whether comorbidities delayed initiation of a DMT or affected the choice of the initial DMT. We hypothesized that the presence of comorbidities would reduce DMT use and influence the choice of DMT for those with MS.

METHODS

Study design and data sources.

We followed a common protocol to conduct this retrospective cohort study in 3 Canadian provinces (British Columbia [BC], Manitoba [MB], and Nova Scotia [NS]).
We used prospectively collected, linked administrative (health claims) and clinical data in each province. Details regarding administrative data used are summarized in Methods appendix e-1 on the Neurology® Web site at Neurology.org; these databases have been used extensively previously.1315 Data linkage was performed at the individual level using a unique personal health number, following which the data were anonymized for analysis. Due to privacy regulations that prevent line level data from leaving the province of origin, analyses were performed in parallel at each site.

Standard protocol approvals, registrations, and patient consents.

The research ethics boards at each site approved the study, while access to administrative data was approved by the relevant body within each province (BC Ministry of Health and Data Stewardship Committee, the Manitoba Health Information Privacy Committee, and the Nova Scotia Department of Health and Wellness).

MS case definition.

Using physician and hospital claims in each province, we defined MS cases as any individual with ≥3 codes for MS using ICD-9/10 (340/G35). This case definition has a positive predictive value of 95% (95% confidence interval [CI] 0.91–0.97).14 Cohort entry (i.e., the index date) was defined as the first recorded MS or demyelinating disease-related claim (ICD-9/10 377.3, 323, 341.9, 341.0/H46, G37, G36.9, G36.0).14 A 5-year run-in period was required to ensure all cases were incident, during which time residency in the province was required and no MS or demyelinating disease codes were allowed. Cases were adults (≥18 years by cohort entry) with the potential incident date ranges determined by the data availability in each province (1989–2012 in MB, 1995–2012 in NS, and 1996–2010 in BC). Table e-1 shows patient selection. Patients were followed until the earliest of DMT initiation, death, emigration from the relevant province, or end of the study (December 31, 2010 in BC; March 31, 2012 in MB and NS).

Comorbidity status.

We applied previously validated algorithms16 to identify whether individuals ever met the case definition for an individual comorbidity (Methods appendix e-1). We used the first claim for the comorbidity as the date of diagnosis. This date was also used to determine whether a comorbidity was present or absent by the index date, and if absent, whether it developed after the index date. Once a comorbidity occurred, it was considered present for the rest of the follow-up. The comorbidities of interest included physical conditions (diabetes, hypertension, hyperlipidemia, ischemic heart disease [IHD], chronic lung disease, epilepsy) and mental conditions (anxiety, depression, bipolar disorder). These comorbidities were selected based on the availability of case definitions with adequate validity,15,16 their effect on other MS outcomes (e.g., disability, quality of life), and potential clinical relevance in the MS population. Comorbidity status at the index date was examined in 2 ways. First, we considered the total number of comorbidities. Because this variable did not meet the proportional hazards assumption, we included the number of comorbidities as a time-dependent continuous variable. Second, we considered the presence of individual comorbidities. Comorbidity status over the entire study period (i.e., comorbidities at the index date and incident comorbidities occurring after the index date) was examined as a time-varying variable: the total number of comorbidities listed above and the presence vs absence of each individual comorbidity at the earliest diagnostic date.

Outcome.

As oral DMTs were not approved during the study period, our analysis focused on the first-line injectable DMTs. The outcome of interest was initiation of a first-line DMT, defined as ≥1 filled prescription of interferon-β (approved in July 1995 in Canada) or glatiramer acetate (approved in September 1997). DMT use was examined as (1) “ever vs never” and (2) choice of initial DMT (glatiramer acetate vs interferon-β).

Statistical analyses.

Potential confounders, measured at the index date, included sex (male as reference group); age, grouped as 18–29 (reference group), 30–39, 40–49, and ≥50 years; and neighborhood-level socioeconomic status (SES) (expressed as quintiles of neighborhood income). The index year was also considered as a potential confounder. To maximize consistency of group sizes and time periods across provinces, groups were as follows: 1995/1996–1999 (reference), 2000–2004, 2005–2010/2012, and also 1989–1994 in MB. The χ2 test was used to examine the association between these potential confounders (outlined above) and each of the outcomes, and between comorbidity status and study outcome. Cox proportional hazards regression models were used to assess the influence of preexisting comorbidities (occurring on or before the index date) on the time from the index date to DMT initiation. Multivariable logistic regression models were built to examine the association between comorbidity status (grouped as 0, 1, 2, and ≥3 comorbidities) before the index date and the choice of initial DMT; these models included only those individuals who initiated one of the 2 injectable DMTs during follow-up and were adjusted for potential confounders (described above). Cox proportional hazards regression models were used to assess the influence of comorbidities (occurring on or after the index date) on the time from the index date to DMT initiation, with incident comorbidities occurring after the index date included as time-varying covariates. All models were adjusted for the same covariates as the logistic models.
Results from each site were pooled via a meta-analysis using random-effects models.17 Heterogeneity between sites was estimated using the I2 statistic.18

Complementary analyses.

To test key assumptions and to fully explore the association between comorbidity status and DMT initiation, complementary analyses were conducted. First, we used an alternative measure of comorbidity status based on the number of prescription drug classes in the year before the index date. Second, we examined the association between DMT initiation and vascular comorbidity, a variable combining diabetes, hypertension, hyperlipidemia, and IHD, given reported associations of vascular comorbidity with MS outcome.8 Third, we repeated the analysis in a restricted cohort in each province with relapsing-onset MS for whom MS-specific clinical data were available. We applied the same analytical approach for complementary analyses as described above (Methods appendix e-1).
Statistical analyses were performed using the Statistical Package for Social Sciences (Chicago, IL),19 R (version 3.0.2),20 and SAS V9.3 (SAS Institute Inc., Cary, NC).

RESULTS

Study populations.

Across the 3 provinces, we identified 10,698 persons with incident MS. Patients in BC were older than those in MB and NS; however, the distributions of sex and SES were consistent across provinces (table 1). Mean age at the index date was higher among participants with comorbidities (p < 0.001, table e-2). Half of these participants had ≥1 comorbidity at the index date (table e-3).
Table 1 Patient characteristics at index date in each study province

Rates of subsequent DMT initiation.

After the index date, 3,170 individuals (29.6%) initiated a DMT. Females and those in younger age groups were more likely to initiate a DMT. Overall, DMT initiation rates were evenly distributed across SES quintiles (table e-4). The most common DMT initiated was interferon-β (table e-3); the proportion of patients who received each interferon-β product did not differ by comorbidity status (table e-5).

Comorbidities and subsequent DMT initiation.

From multivariable analyses, the number of comorbidities was associated with a time-dependent reduction in the likelihood of initiating a DMT. At 1 year from the index date, a one unit increase in the number of comorbidities was associated with a 10% reduction in the likelihood of initiating a DMT (adjusted hazard ratio [aHR] 0.90; 95% CI 0.84–0.96), and with a reduction of 42% in the likelihood of DMT initiation (aHR 0.58; 95% CI 0.42–0.80) at year 5 (figure 1). Results were consistent when examining cumulative comorbidities over the study period using a time-varying model (figure 1).
Figure 1 Association between number of comorbidities and the likelihood of disease-modifying therapy (DMT) initiation
aResults were obtained from Cox proportional hazards models with comorbidity count at index date as a time-dependent variable (i.e., count × time). bResults were obtained from Cox proportional hazard models with comorbidity count during follow up as a time-varying variable. Models were adjusted for age, sex, year of index date, and socioeconomic status. CI = confidence interval.
When examining each individual comorbidity at the index date, individuals with IHD had a lower likelihood of initiating a DMT vs those without IHD at the index date (aHR 0.72; 95% CI 0.59–0.87, figure 2). The direction and magnitude of findings were similar for anxiety (figure 2). The reduced likelihood of initiating a DMT in patients with IHD or anxiety was consistent across age groups, although with the smaller sample sizes, most findings did not reach statistical significance (figures e-1 to e-4).
Figure 2 Each individual comorbidity at the index date and the hazard ratios (HRs) of subsequent disease-modifying therapy (DMT) initiationa
aResults were obtained from time-fixed Cox proportional hazards models. Reference group was patients without each individual comorbidity and comorbidity by the index date. Model was adjusted for age, sex, year of index date, and socioeconomic status. CI = confidence interval.
Individuals with hyperlipidemia, chronic lung diseases, or bipolar disorder at the index date were also less likely to initiate a DMT, although the hazard ratios for these 3 comorbidities included 1 (figure 2). Depression at the index date was associated with a 13% relative increase in the likelihood of initiating a DMT compared to those who did not have depression (aHR 1.13; 95% CI 1.00–1.27, p = 0.05; figure 2). From the time-varying multivariable Cox proportional hazards model, individual comorbidities during the study period were not associated with DMT initiation (data not shown).

Comorbidities and choice of initial DMT.

Based on multivariable logistic regression models, and among the patients who initiated 1 of the 2 DMTs during follow-up, neither the number of comorbidities (figure 3) nor individual comorbidities at the index date was associated with the DMT choice (data not shown). These findings were consistent after substituting comorbidity as a continuous variable to assess a dose-response type effect (data not shown). In all models, none of the covariates was associated with the choice of initial DMT (data not shown).
Figure 3 Total number of comorbidities by the index date and choice of initial disease-modifying therapy received
aThe comorbidities of interest included diabetes, hypertension, hyperlipidemia, heart disease, chronic lung disease, epilepsy, anxiety, depression, and bipolar disorder. bReference groups were patients with no (0) comorbidity by the index date. Models were adjusted for age, sex, year of index date, and socioeconomic status. cResults were obtained from logistic regression models. Odds ratios represent the relative odds of receiving glatiramer acetate compared to the odds of receiving interferon-β among those without comorbidities by the index date. CI = confidence interval.

Complementary analyses.

When the number of prescription drug classes in the year before the index date was used instead of the number of comorbidities, the effect estimate was in the same direction, although the findings did not reach statistical significance (figures e-5 and e-6). Combined vascular comorbidity was not associated with DMT initiation. Restricting our cohort to those with MS-specific clinical data resulted in 3,686 individuals with incident relapsing-onset MS (table e-1). Findings in this subcohort were consistent with the primary analyses (figures e-7 and e-8).

DISCUSSION

In this cohort study of 10,698 incident MS cases, we observed effects of comorbidities on the initiation of a DMT for MS. We found that the greater the number of comorbidities, the lower the likelihood that a DMT for MS was started. When examining individual comorbidities, IHD and anxiety were associated with a reduction in the likelihood of subsequent DMT initiation.
We were unable to find previous studies that examined the association between comorbidity and DMT initiation or choice of initial DMT in MS. However, our observation that as the number of comorbidities increased, the likelihood of DMT initiation decreased, is consistent with other chronic diseases such as cancer and diabetes, in which increasing comorbidity burden delays treatment initiation.11,2123 For primary care physicians and patients, multiple chronic conditions may serve as competing demands on time or act as barriers that may influence access to and decisions regarding treatment.24,25 In the context of our study in Canada, where DMT treatment is initiated by a specialist, this delay in treatment initiation may reflect diagnostic delays due to the presence of comorbidity, as diagnostic delays have been shown in the US-based North American Research Committee on MS registry.7 Similar diagnostic delays in the presence of comorbidity have also been shown in rheumatoid arthritis26 and cancer.27
We found that IHD and anxiety were strongly associated with a decreased likelihood of initiating a DMT. Other conditions, such as hyperlipidemia, chronic lung diseases, and bipolar disorder, also exhibited similar associations, though none reached significance, possibly because a smaller number of individuals were affected. A possible reason for this association in patients with IHD, one also likely to be present for patients with hyperlipidemia and chronic lung diseases, is that they are already burdened with multidrug regimens. This greater number of concurrent drug therapies is likely to affect patients' and physicians' decisions regarding initiating another treatment. Perceived benefits of therapy may also be less when multiple chronic conditions affect health status.
Our findings regarding the negative impact of anxiety and bipolar disorder on DMT initiation are consistent with findings in other chronic diseases.21,28 Mental health comorbidities can impair communication between patients and clinicians, interfere with self-management and the ability to follow treatment recommendations, or amplify concerns regarding drug treatment.29,30 Additionally, patients with an anxiety disorder may decline treatment when offered due to needle phobia or fear of adverse effects; needle phobia has been suggested as a predictor of nonadherence or discontinuation of MS drugs in previous reports.3133 Thus identification of patients with preexisting anxiety is important for health professionals to provide appropriate and sufficient medical interventions. Unexpectedly, we found comorbid depression to be associated with an increased likelihood of initiating a DMT in our study, although the hazard ratio only reached marginal statistical significance. This finding contrasts with studies that have reported a decreased likelihood of treatment initiation in patients with diabetes or cancer who had comorbid depression.21,28 We can speculate that patients with preexisting depression may have had more active (MS) disease compared to those who did not,34 prompting the decision to initiate DMT treatment. However, we do not know the status of depression (active, in remission) at the time treatment decisions were made and further study will be needed to explore this possible relationship. We did not find an association between presence of depression and the choice of DMT received. This is of interest given the early safety concerns regarding a possible increased risk of suicide and depression in relation to interferon-β use,3537 although subsequent studies had mixed findings.38
We observed variation across provinces, highlighting the value of a multisite study and pooled analyses. For instance, the increased likelihood of initiating a DMT associated with the presence of depression is mainly attributable to the association between depression and DMT initiation in Manitoba; hypertension was associated with an almost 50% reduced likelihood of DMT initiation in British Columbia but this was not observed in Manitoba or Nova Scotia. This apparent difference in prescribing practices across provinces may reflect the gap in knowledge regarding the effectiveness and safety of DMTs in individuals with MS and comorbid conditions as such individuals are typically excluded from clinical trials. Findings such as this highlight the need to better understand the optimal treatment approaches in patients with MS and comorbidities, and to develop an evidence base to better support clinical decision-making in this population.
Our study's strengths include that it was population-based and we identified a large study population using a validated MS case definition. However, our study also had limitations. For example, comorbidity onset could be misclassified in patients who infrequently access the health system, possibly underestimating or overestimating the impact of comorbidities on DMT use. Our case definitions for comorbidity were highly specific, but definitions for IHD and anxiety were less sensitive,15,39 thus we have not captured all cases of each comorbidity, which might be expected to bias our findings toward the null. Individuals with MS onset late in the study period might not have had time to meet our case definition. We were unable to determine whether depression or anxiety reflected early prodromal symptoms of MS or occurred independently. However, there are no data that suggest that MS treatment decisions would differ according to the presumed etiology of an existing mood disturbance. The presence of these conditions is relevant if they delay initiation of a DMT in MS, regardless of the etiology. The mean age at MS diagnosis was higher than reported in some studies, but is comparable to that reported in other studies using similar methods.13,40 A later age of diagnosis may lead to a higher prevalence of comorbidity at diagnosis but would not affect the association between comorbidity and DMT initiation. Indicators of MS disease activity or comorbid condition severity were not available to us and would be of value to explore in future studies where this level of detail is available. The number of years of data available varied by province. However, all data began before the DMTs first became available in Canada and follow-up periods were substantially longer than the median time to DMT initiation. The different follow-up times would not be expected to affect our findings. Finally, a small number of patients who did not initiate DMT may not have been eligible for treatment under their provincial governments' schemes for drug reimbursement; however, we were able to confirm our main findings in subgroups where these clinical data were available. Nonetheless, our findings require replication.
This multi-province, population-based cohort study revealed that comorbidities influence the use of DMT in incident MS. As the number of current comorbidities increased, the likelihood of DMT initiation decreased. Mental comorbidities such as anxiety had a significant impact on subsequent DMT initiation. Individuals with MS and multiple comorbidities likely require more health services and more complex health management strategies. A better understanding of the effects of comorbidity on the effectiveness and safety of DMTs is needed to support clinical decision-making, as our findings suggest that individuals with these conditions may be treated differently with respect to access to MS-specific drug therapies in the absence of supporting evidence.

GLOSSARY

aHR
adjusted hazard ratio
BC
British Columbia
CI
confidence interval
DMT
disease-modifying therapy
ICD-9/10
International Classification of Diseases–9 or 10
IHD
ischemic heart disease
MB
Manitoba
MS
multiple sclerosis
NS
Nova Scotia
SES
socioeconomic status

ACKNOWLEDGMENT

All inferences, opinions, and conclusions drawn in this publication are those of the authors and do not reflect the opinions or policies of the Data Stewards. No official endorsement by Manitoba Health, Population Data BC, Pharmanet, or the Regie D'Assurance Maladie du Quebec is intended or should be inferred. Some data used in this report were made available by Health Data Nova Scotia of Dalhousie University. Although this research is based on data obtained from the Nova Scotia Department of Health and Wellness, the observations and opinions expressed of those of the authors and do not represent those of either Health Data Nova Scotia or the Department of Health and Wellness. The authors thank the following contributors: Patricia Caetano, PhD (University of Manitoba, policy consultant); Nicholas Hall, BSc (University of Manitoba, study coordinator); Yan Wang (Dalhousie University, analytic support); Larry Svenson, BSc (University of Alberta, Collaborator).

Data Supplement

Five tables, eight tables, and methods; one PDF file and one Microsoft Word file.
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited. © 2016 American Academy of Neurology. Files in this Data Supplement:
e-Methods - Microsoft Word file

Supplementary Material

File (coinvestigators.doc)
File (e-methods.docx)
File (tables-figures.pdf)

REFERENCES

1.
Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 2005;81:302–308.
2.
Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013;6:CD008933.
3.
Simpson RJ, McLean G, Guthrie B, Mair F, Mercer SW. Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis. BMC Neurol 2014;14:128.
4.
Rochon PA, Katz JN, Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability: a prospective comparison of three comorbidity indices. Med Care 1996;34:1093–1101.
5.
Tettey P, Simpson S, Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 2014;20:1737–1744.
6.
Moccia M, Lanzillo R, Palladino R, et al. The Framingham cardiovascular risk score in multiple sclerosis. Eur J Neurol 2015;22:1176–1183.
7.
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009;72:117–124.
8.
Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041–1047.
9.
Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007;11:597–613.
10.
FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm. Accessed September 21, 2015.
11.
Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013;5(suppl 1):3–29.
12.
Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, de Zeeuw D, Stolk RP, Denig P. Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus: a cohort study. PLoS One 2012;7:e38707.
13.
Kingwell E, Zhu F, Marrie RA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010). J Neurol 2015;262:2352–2363.
14.
Marrie RA, Fisk JD, Stadnyk KJ, et al. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Can J Neurol Sci 2013;40:824–831.
15.
Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 2013;13:16.
16.
Marrie RA, Yu BN, Leung S, et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 2013;40:85–92.
17.
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
18.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
19.
IBM Corp. Released. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.; 2013.
20.
R Core Team. R: A Language and Environment for Statistical Computing [computer program]. Version 3.0.2. Vienna, Austria: R Foundation for Statistical Computing; 2013.
21.
Vitry AI, Roughead EE, Preiss AK, et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort study. PLoS One 2010;5:e14024.
22.
Parchman ML, Pugh JA, Romero RL, Bowers KW. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med 2007;5:196–201.
23.
Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 2010;29:106–117.
24.
Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia. Can Brain 2012;135:2973–2979.
25.
Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: a model for the delivery of clinical preventive services. J Fam Pract 1994;38:166–171.
26.
Tavares R, Pope JE, Tremblay JL, et al. Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. J Rheumatol 2012;39:2088–2097.
27.
Winget M, Hossain S, Yasui Y, Scarfe A. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer 2010;116:4849–4856.
28.
Boyd CA, Benarroch-Gampel J, Sheffield KM, Han Y, Kuo YF, Riall TS. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Surgery 2012;152:403–413.
29.
Pan A, Lucas M, Sun Q, et al. Increased mortality risk in women with depression and diabetes mellitus. Arch Gen Psychiatry 2011;68:42–50.
30.
Koroukian SM, Xu F, Beaird H, Diaz M, Murray P, Rose JH. Complexity of care needs and unstaged cancer in elders: a population-based study. Cancer Detect Prev 2007;31:199–206.
31.
Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551–554.
32.
Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006;38:167–171.
33.
Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69–77.
34.
Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology 2005;64:359–360.
35.
Fragoso YD, Frota ER, Lopes JS, et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol 2010;33:312–316.
36.
Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998;4:487–489.
37.
Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552–554.
38.
Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175–181.
39.
Marrie RA, Yu BN, Leung S, et al. Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Relat Disord 2013;2:355–361.
40.
Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014;85:76–84.

Information & Authors

Information

Published In

Neurology®
Volume 86Number 14April 5, 2016
Pages: 1287-1295
PubMed: 26944268

Publication History

Received: July 24, 2015
Accepted: December 21, 2015
Published online: March 4, 2016
Published in print: April 5, 2016

Permissions

Request permissions for this article.

Disclosure

T. Zhang receives a Post-Doctoral Fellowship Award from the Multiple Sclerosis Society of Canada (2014–2016). H. Tremlett is funded by the Multiple Sclerosis Society of Canada (Don Paty Career Development Award) and is a Michael Smith Foundation for Health Research Scholar and the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. She has received research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, and the UK MS Trust; speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres (2013), the National MS Society (2012, 2014), Bayer Pharmaceuticals (2010), Teva Pharmaceuticals (2011), ECTRIMS (2011, 2012, 2013, 2014), UK MS Trust (2011), the Chesapeake Health Education Program, US Veterans Affairs (2012), Novartis Canada (2012), Biogen Idec (2014), and American Academy of Neurology (2013, 2014, 2015). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group. S. Leung, F. Zhu, and E. Kingwell report no disclosures relevant to the manuscript. J. Fisk receives research grant and training program support from the Canadian Institutes of Health Research, the National Multiple Sclerosis Society, and the Multiple Sclerosis Society of Canada; and has received speaker honoraria from EMD Serono (2013, 2014). V. Bhan has received honoraria and consulting fees from Biogen Idec, EMD Serono, Genzyme, Novartis, Roche, and Teva Neurosciences. T. Campbell has received honoraria from Biogen Idec Canada, Teva Canada Innovation, EMD Serono, Genzyme, and Novartis; support for travel from Biogen Idec, Teva Canada Innovation, EMD Serono, and Genzyme; grant support from Biogen Idec Canada Inc. and Novartis; and research support from Biogen Idec Canada Inc. K. Stadnyk reports no disclosures relevant to the manuscript. B. Yu receives research funding from Health Science Centre Foundation, Canadian Institutes of Health Research, Gilead Sciences, Canadian International Development Agency, the Multiple Sclerosis Society of Canada, and National Multiple Sclerosis Society (USA). R.A. Marrie receives research funding from Canadian Institutes of Health Research, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, National Multiple Sclerosis Society, and Rx & D Health Research Foundation, and has conducted clinical trials funded by Sanofi-Aventis. Go to Neurology.org for full disclosures.

Study Funding

Supported in part by the Canadian Institutes of Health Research (CIBG 101829), the Rx & D Health Research Foundation, a Don Paty Career Development award from the Multiple Sclerosis Society of Canada (to R.A.M.), and Manitoba Research Chair from Research Manitoba (to R.A.M.). The funding sources had no role in the study design, collection, analysis or interpretation of the data, or in the decision to submit the article for publication. The Article Processing Charge was paid by CIHR.

Authors

Affiliations & Disclosures

Tingting Zhang, MD, PhD
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Multiple Sclerosis of Canada, Post-Doctoral Fellowship Award (2014/2015-2015/2016)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Helen Tremlett, PhD
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
All non-profit: ? National US surveillance system for MS. 2013-present. Invited by the US National MS Society to form an advisory group to enable the development of a national surveillance system capable of tracking the incidence and prevalence of MS. Monthly teleconferences; one face-to-face meeting: Atlanta, Georgia (March 2014) Status: Bipartisan legislation introduced to Congress - ?Advancing Research for Neurological Diseases Act, H.R. 292.?to guide the Centers for Disease Control and Prevention in tracking the incidence and prevalence of neurological diseases, including Multiple Sclerosis and Parkinson?s disease [13th-Jan-2015; http://burgess.house.gov/blog/? postid=397459] ? Scientific Advisory Board member, ?A randomized controlled trial of vitamin D in multiple sclerosis.?Investigator initiated study funded by the US National MS Society. PI: (Dr Ellen Mowry). Study location: USA: University of California, San Francisco; Johns Hopkins University; University of Pennsylvania; Washington University St. Louis, Virginia Mason Medical Center; Oregon Health & Science University; Mt. Sinai School of Medicine; Cleveland Clinic; University of Vermont; Yale University (October 2012-2013) ? Multiple Sclerosis International Federation advisory group for the ?Atlas of MS? 2013 update. Website: http://www.atlasofms.org/ This international, interactive on-line resource is well used by the MS community and endorsed by the World health Organization (http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf ). Established in 2006, it needs updating, but requires input from the MS community. Personal role: identifying key experts in MS required to populate the website; completing Canada?s section on epidemiology & MS; generating interest in the website; presented results at international conference (Copenhagen Oct/ 2013). Sept 2012-Dec 2013
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Helen Tremlett has received funding from the Multiple Sclerosis Society of Canada (Don Paty Career Development Award); is the Michael Smith Foundation for Health Research Scholar Award and the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. She has received: research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, and the UK MS Trust; speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres (2013), the National MS Society (2012, 2014), Bayer Pharmaceuticals (2010), Teva Pharmaceuticals (2011), ECTRIMS (2011, 2012, 2013, 2014, 2015), UK MS Trust (2011), the Chesapeake Health Education Program, US Veterans Affairs (2012), Novartis Canada (2012), Biogen Idec (2014), American Academy of Neurology (2013, 2014, 2015). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Canadian Institutes of Health Research [#190898 (PI) and #MOP-82738 (PI) and MOP-119393 (PI) and MOP-106607 (PI)]; the US National Multiple Sclerosis Society (Operating grants: 2006-09; 2009-12; 2012-15; 2014-17), the Multiple Sclerosis Society of Canada (2015-18; EGID #2624 (PI)) the Multiple Sclerosis Society of Canada (Don Paty Career Development Award, 2004-2014), and a Michael Smith Foundation for Health Research Scholar Award (2006- 2014); Canada Research Chair in Neuroepidemiology and Multiple Sclerosis
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Stella Leung, MSc
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Feng Zhu, MSc
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Elaine Kingwell, PhD
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John D. Fisk, PhD
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
EMD Serono, Travel expenses and $1500 honourarium for workshop participation (June 2014).
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1)CIHR operating grant, ?Early and preclinical diagnosis of Parkinson's disease using olfactory testing and Diffusion Tensor Imaging of olfactory bulb and substantia nigra.? 2012-2017, Co-investigator. (2)CIHR Team Grant, ?Defining the burden and managing the effects of psychiatric comorbidity in chronic immunoinflammatory disease.? 07/2014-06/2019,Co- investigator. (3)CIHR ? Emerging Team Grant: “Co-morbidity of brain disorders and other health problems” 2010?2015, Co- investigator. (4) CIHR operating grant, ?Epidemiology of cognitive dynamics in older adults? 2010 -2015, Co-investigator (5) CIHR catalyst grant (Exploring ADNI and other Neuroimaging Databases to benefit the early detection of Alzheimer's Disease and Related Dementias),?Alternative FDG-PET relative standardized uptake value metrics for the assessment of early metabolic biomarkers of Alzheimer's disease.? 2014-2016, Co-investigator. (6) CIHR catalyst grant (Exploring ADNI and other Neuroimaging Databases to benefit the early detection of Alzheimer's Disease and Related Dementias)?Pre- symptomatic biomarkers for Alzheimer?s disease: Structural and functional changes in white matter and brain connectivity.? 2014-2016, Co-investigator.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
National MS Society operating Grant ?Prodromal Multiple Sclerosis: The PrOMS Study?. 2016 - 2018, Co- investigator.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
Fatigue Impact Scale and Daily Fatigue Impact Scale, Licensing and Distribution agreement with MAPI Research Trust.
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Virender Bhan, MBBS
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
Dr. V.Bhan received personal compensation for serving on scientific Advisory Boards for Biogen Canada, EMD Serono, Genzyme Canada, Roche and Novartis pharmaceuticals.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Dr. V. Bhan received speaker honoraria from Biogen, EMD Serono, Genzyme and Novartis pharmaceuticals.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Trudy L. Campbell, MN, NP
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Biogen Idec Canada (2) Genzyme Canada (3) Novartis Canada
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Karen Stadnyk, MSc
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
B. Nancy Yu, MD, PhD
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Building capacity to respond to HIV/AIDS in China/CIDA, co-investigator, 01/04/2007 to 31/03/2013. (2) Burden of diabetes in Manitoba/PHAC (via Manitoba Health & Healthy Living), Principal Investigor, 01/04/09 to 31/03/2010. (3)The development of a surveillance tool for Chronic Kidney Disease and End Stage Renal Disease in Manitoba/PHAC, co-applicant, 01/07/2009 to 31/07/2011.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
CIHR ($2,498,495, 2013/4 - 2018/3), Advancing primary healthcare for persons living with HIV in Canada, co- investigator, PI Dr. Clare Liddy. Multiple Sclerosis Society of Canada ($155,599, 2012/7 - 2015/6), The impact of comorbidity and secular time on hospitalizations and mortality in MS, co-investigator, PI Dr. Ruth Ann Marrie. National Multiple Sclerosis Society ($317,843, 2012/7- 2015/6), Adherence to immunomodulators in Multiple Sclerosis: prevalence and clinical impact (the AIMS Study), collaborator, PI Dr. Helen Tremlett. CIHR Emerging Team Grant ($1,500,000, 2010/4 - 2015/3), Team in the epidemiology & impact of comorbidity on MS (ECoMS), co-investigator, PI Dr. Ruth Ann Marie. Gilead Sciences ($96,000, 2013/4 - 2014/3). Missed opportunities for diagnosis for HIV epidemiological study (MODES Manitoba), co-investigator, PI Dr. Marissa Becker. CIDA(International development grant, $20,000), Building capacity to respond to HIV/AIDS in China: Extending the impact. Co-investigator, PI Dr. James Blanchard. CIHR Emerging Team: HIV/AIDS vaccine discovery and social research ($750,000), Team in the socio-cultural aspects of implementing HIV vaccine programs among MSM and FSWs in Asia and Africa. co-investigator, PI Dr. Robert Lorway. CIDA (International development grant, $990,000), Capacity building to respond to HIV/AIDS in China. Co- investigator, PI Dr. James Blanchard.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ruth Ann Marrie, MD, PhD
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neurology, Editorial Board Multiple Sclerosis Journal, Editorial Board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Received support as site Principal Investigator for clinical trials from Sanofi-Aventis (2007-2014)
Research Support, Government Entities:
1.
Received support as principal investigator from the Canadian Institutes of Health Research (2010-2019), the Public Health Agency of Canada (2010-2013), and Research Manitoba (2014-2019).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2016) and the National Multiple Sclerosis Society (2013-2015), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2015). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014). Rx & D Health Research Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
For the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis
From the Department of Medicine, Division of Neurology and Centre for Brain Health (T.Z., H.T., F.Z., E.K.), University of British Columbia, Vancouver; Department of Community Health Sciences (S.L., B.N.Y., R.A.M.), University of Manitoba, Winnipeg; Departments of Medicine (J.D.F., V.B., T.L.C.) and Psychiatry (J.D.F.) and School of Nursing (T.L.C.), Dalhousie University, Halifax, Nova Scotia; and Queen Elizabeth II Health Sciences Centre (J.D.F., V.B., T.L.C., K.S.), Nova Scotia Health Authority, Halifax, Canada.

Notes

Correspondence to Dr. Marrie: [email protected]
Coinvestigators are listed on the Neurology® Web site at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the Canadian Institutes of Health Research.

Author Contributions

The corresponding author (R.A.M.) takes responsibility for the integrity of the data and the accuracy of the data analysis. The analysts and principal investigators at each site had full access to the data at each site (BC: Helen Tremlett, Feng Zhu, Tingting Zhang; MB: Ruth Ann Marrie, Stella Leung; NS: John Fisk, Yan Wang). Ruth Ann Marrie, John Fisk, and Helen Tremlett designed the study and obtained funding. All authors contributed to the interpretation of the data. Tingting Zhang drafted the manuscript. All authors revised the manuscript and approved the final version to be published.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Association of depression in multiple sclerosis with fatigue, sleep disturbances, disability, and health-related quality of life: Outcomes of a cross-sectional study, Neurology Perspectives, 5, 1, (100181), (2025).https://doi.org/10.1016/j.neurop.2024.100181
    Crossref
  2. Comorbidity in the multiple sclerosis clinic , Advances in Clinical Neuroscience & Rehabilitation, (2024).https://doi.org/10.47795/QORZ6739
    Crossref
  3. Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects, Frontiers in Bioscience-Landmark, 29, 11, (2024).https://doi.org/10.31083/j.fbl2911386
    Crossref
  4. Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?, Current Neuropharmacology, 22, 8, (1286-1326), (2024).https://doi.org/10.2174/1570159X22666240124114126
    Crossref
  5. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years, Neurology, 103, 2, (2024)./doi/10.1212/WNL.0000000000209574
    Abstract
  6. Impact of multiple sclerosis comorbidities on quality of life and job activity, Multiple Sclerosis Journal, 30, 8, (1047-1055), (2024).https://doi.org/10.1177/13524585241260550
    Crossref
  7. Comorbidities and their association with outcomes in the multiple sclerosis population: A rapid review, Multiple Sclerosis and Related Disorders, 92, (105943), (2024).https://doi.org/10.1016/j.msard.2024.105943
    Crossref
  8. Clinical and demographic characteristics of late-onset multiple sclerosis: LOMS-TR study, Multiple Sclerosis and Related Disorders, 84, (105469), (2024).https://doi.org/10.1016/j.msard.2024.105469
    Crossref
  9. Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study, The Lancet Regional Health - Americas, 29, (100667), (2024).https://doi.org/10.1016/j.lana.2023.100667
    Crossref
  10. Current understanding of cardiovascular autonomic dysfunction in multiple sclerosis, Heliyon, 10, 15, (e35753), (2024).https://doi.org/10.1016/j.heliyon.2024.e35753
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share